NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00173-0752-00 | 00173-0752 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Mar 16, 2007 | Nov 30, 2017 | No Longer Used |
00480-3237-51 | 00480-3237 | Lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Dec 19, 2024 | In Use | |
72205-0030-92 | 72205-0030 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 10, 2019 | In Use | |
67184-0531-01 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
40051-0609-13 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
60505-4327-03 | 60505-4327 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Nov 23, 2018 | Aug 11, 2021 | In Use |
57894-0155-12 | 57894-0155 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Feb 9, 2018 | In Use | |
69660-0202-91 | 69660-0202 | Rucaparib | Rubraca | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | May 1, 2017 | Jul 31, 2025 | In Use |
57894-0150-25 | 57894-0150 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Sep 1, 2015 | Aug 31, 2018 | In Use |
16729-0051-53 | 16729-0051 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
47335-0893-21 | 47335-0893 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
71334-0100-01 | 71334-0100 | Ivosidenib | Tibsovo | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Jul 20, 2018 | Nov 30, 2024 | No Longer Used |
16571-0821-41 | 16571-0821 | Temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
71921-0178-20 | 71921-0178 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Aug 15, 2022 | In Use | |
40051-0609-52 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
67877-0542-07 | 67877-0542 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sep 29, 2020 | In Use | |
60505-4512-03 | 60505-4512 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 8, 2023 | Dec 31, 2025 | In Use |
40051-0609-53 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
62559-0925-51 | 62559-0925 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Oct 31, 2022 | No Longer Used |
72694-0617-60 | 72694-0617 | Ivosidenib | Tibsovo | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Oct 19, 2021 | In Use | |
58181-4351-04 | 58181-4351 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 1, 2025 | In Use | |
69539-0318-92 | 69539-0318 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 26, 2024 | In Use | |
68462-0135-08 | 68462-0135 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Oct 16, 2019 | In Use | |
00085-1417-03 | 00085-1417 | Temozolomide | Temodar | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use |
Found 11564 results — Export these results